Objective: To probe into the clinical efficacy and safety of mycophenolate mofetil in the treatment of recurrent ocular myasthenia gravis (OMG) in children. Methods: Clinical data and follow-up of 5 patients with OMG treated with mycophenolate mofetil and admitted into the pediatric neurology department of Chengdu Women’ s and Children’ s Central Hospital from 2017 to 2021 were analyzed. Results: Onset age of 5 children was from 14 to 28 months old

and the course of disease was from 21 to 94 months before application of mycophenolate mofetil. All 5 patients received hormones

hormones + pyridine bromide alone or in combination therapy before receiving mycophenolate mofetil therapy

with multiple (⩾2) recurrences. In the last recurrence

all patients received oral low-dose prednisone and mycophenolate mofetil in the acute stage. After stabilization

prednisone was reduced and mycophenolate mofetil alone was administered. Follow-up was as short as 18 months and as long as 28 months

and there was no recurrence. No significant adverse drug reactions were observed during follow-up

and hormone-related side effects were alleviated with drug withdrawal of hormone. Conclusion: For children with recurrent ocular myasthenia gravis

mycophenolate mofetil may be the safe and effective treatment

which still needs to be further confirmed by a large sample of randomized controlled trials (RCT).